Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: NKLA stock price vs ARCT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ARCT's multiple
Needs ARCT P/S.
Implied fair value · at NKLA's multiple
Needs NKLA P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: NKLA FY 2022 (ended Dec 31, 2022) · ARCT FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Nikola Corporation · implied price per share
Bear
-$1.54
Base
-$1.82
Bull
-$2.09
ARCTURUS THERAPEUTICS HOLDINGS INC. · implied price per share
Bear
-$2.12
Base
-$2.50
Bull
-$2.87
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.83x
0.47x
Net debt / EBITDA
Leverage against operating earnings
-0.10x
2.04x
Cash and equivalents
Liquid reserves on the balance sheet
$104.30M
$230.91M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Tesla, Inc.
NKLA vs TSLA
FORD MOTOR CO
NKLA vs F
General Motors Co
NKLA vs GM
Rivian Automotive, Inc. / DE
NKLA vs RIVN
Lucid Group, Inc.
NKLA vs LCID
PACCAR INC
NKLA vs PCAR
Moderna, Inc.
NKLA vs MRNA
BioNTech SE
NKLA vs BNTX
ALNYLAM PHARMACEUTICALS, INC.
NKLA vs ALNY
Sarepta Therapeutics, Inc.
NKLA vs SRPT
Intellia Therapeutics, Inc.
NKLA vs NTLA
$196.80M
$101.29M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
